Tonix Pharmaceuticals Holding Corp. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Thomas Englese, who has served as Executive Vice President of Commercial Operations since September 2024, was promoted to Chief Commercial Officer of Tonix Pharmaceuticals effective immediately on September 8, 2026. Englese will continue leading sales, marketing, and commercial operations for TONMYA (fibromyalgia treatment), Zembrace SymTouch, and Tosymra. No financial terms, equity grants, or compensation changes are disclosed in the filing.
Why this rating
Standard C-suite promotion of existing executive with established track record. No material financial impact, strategic pivots, or business changes disclosed. Routine organizational restructuring.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.